Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 44

    1.

    Survival gains needed to offset persistent adverse treatment effects in localised prostate cancer.

    King MT, Viney R, Smith DP, Hossain I, Street D, Savage E, Fowler S, Berry MP, Stockler M, Cozzi P, Stricker P, Ward J, Armstrong BK.

    Br J Cancer. 2012 Feb 14;106(4):638-45. doi: 10.1038/bjc.2011.552. Epub 2012 Jan 24.

    PMID:
    22274410
    [PubMed - indexed for MEDLINE]
    2.

    Changes in circulating microRNA levels associated with prostate cancer.

    Bryant RJ, Pawlowski T, Catto JW, Marsden G, Vessella RL, Rhees B, Kuslich C, Visakorpi T, Hamdy FC.

    Br J Cancer. 2012 Feb 14;106(4):768-74. doi: 10.1038/bjc.2011.595. Epub 2012 Jan 12.

    PMID:
    22240788
    [PubMed - indexed for MEDLINE]
    3.

    Salinomycin inhibits prostate cancer growth and migration via induction of oxidative stress.

    Ketola K, Hilvo M, Hyötyläinen T, Vuoristo A, Ruskeepää AL, Orešič M, Kallioniemi O, Iljin K.

    Br J Cancer. 2012 Jan 3;106(1):99-106. doi: 10.1038/bjc.2011.530.

    PMID:
    22215106
    [PubMed - indexed for MEDLINE]
    4.

    Investigating prostate cancer tumour-stroma interactions: clinical and biological insights from an evolutionary game.

    Basanta D, Scott JG, Fishman MN, Ayala G, Hayward SW, Anderson AR.

    Br J Cancer. 2012 Jan 3;106(1):174-81. doi: 10.1038/bjc.2011.517. Epub 2011 Dec 1.

    PMID:
    22134510
    [PubMed - indexed for MEDLINE]
    5.

    Risk of prostate cancer in a population-based cohort of men with coeliac disease.

    Ludvigsson JF, Fall K, Montgomery S.

    Br J Cancer. 2012 Jan 3;106(1):217-21. doi: 10.1038/bjc.2011.536. Epub 2011 Dec 1.

    PMID:
    22134505
    [PubMed - indexed for MEDLINE]
    6.

    Dissecting the expression of EEF1A1/2 genes in human prostate cancer cells: the potential of EEF1A2 as a hallmark for prostate transformation and progression.

    Scaggiante B, Dapas B, Bonin S, Grassi M, Zennaro C, Farra R, Cristiano L, Siracusano S, Zanconati F, Giansante C, Grassi G.

    Br J Cancer. 2012 Jan 3;106(1):166-73. doi: 10.1038/bjc.2011.500. Epub 2011 Nov 17.

    PMID:
    22095224
    [PubMed - indexed for MEDLINE]
    7.

    Identification of markers of prostate cancer progression using candidate gene expression.

    Larkin SE, Holmes S, Cree IA, Walker T, Basketter V, Bickers B, Harris S, Garbis SD, Townsend PA, Aukim-Hastie C.

    Br J Cancer. 2012 Jan 3;106(1):157-65. doi: 10.1038/bjc.2011.490. Epub 2011 Nov 10.

    PMID:
    22075945
    [PubMed - indexed for MEDLINE]
    8.

    Tumour suppressors miR-1 and miR-133a target the oncogenic function of purine nucleoside phosphorylase (PNP) in prostate cancer.

    Kojima S, Chiyomaru T, Kawakami K, Yoshino H, Enokida H, Nohata N, Fuse M, Ichikawa T, Naya Y, Nakagawa M, Seki N.

    Br J Cancer. 2012 Jan 17;106(2):405-13. doi: 10.1038/bjc.2011.462. Epub 2011 Nov 8.

    PMID:
    22068816
    [PubMed - indexed for MEDLINE]
    9.

    The role of diet and physical activity in breast, colorectal, and prostate cancer survivorship: a review of the literature.

    Davies NJ, Batehup L, Thomas R.

    Br J Cancer. 2011 Nov 8;105 Suppl 1:S52-73. doi: 10.1038/bjc.2011.423. Review.

    PMID:
    22048034
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    10.

    Long-term health outcomes in a British cohort of breast, colorectal and prostate cancer survivors: a database study.

    Khan NF, Mant D, Carpenter L, Forman D, Rose PW.

    Br J Cancer. 2011 Nov 8;105 Suppl 1:S29-37. doi: 10.1038/bjc.2011.420.

    PMID:
    22048030
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    11.

    Phase I study of BIBF 1120 with docetaxel and prednisone in metastatic chemo-naive hormone-refractory prostate cancer patients.

    Bousquet G, Alexandre J, Le Tourneau C, Goldwasser F, Faivre S, de Mont-Serrat H, Kaiser R, Misset JL, Raymond E.

    Br J Cancer. 2011 Nov 22;105(11):1640-5. doi: 10.1038/bjc.2011.440. Epub 2011 Oct 25.

    PMID:
    22027711
    [PubMed - indexed for MEDLINE]
    12.

    Androgen deprivation therapy as adjuvant/neoadjuvant to radiotherapy for high-risk localised and locally advanced prostate cancer: recent developments.

    Payne H, Mason M.

    Br J Cancer. 2011 Nov 22;105(11):1628-34. doi: 10.1038/bjc.2011.385. Epub 2011 Oct 18. Review.

    PMID:
    22009028
    [PubMed - indexed for MEDLINE]
    13.

    Highly sensitive molecular diagnosis of prostate cancer using surplus material washed off from biopsy needles.

    Bermudo R, Abia D, Mozos A, García-Cruz E, Alcaraz A, Ortiz AR, Thomson TM, Fernández PL.

    Br J Cancer. 2011 Nov 8;105(10):1600-7. doi: 10.1038/bjc.2011.435. Epub 2011 Oct 18.

    PMID:
    22009027
    [PubMed - indexed for MEDLINE]
    14.

    BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients.

    Kote-Jarai Z, Leongamornlert D, Saunders E, Tymrakiewicz M, Castro E, Mahmud N, Guy M, Edwards S, O'Brien L, Sawyer E, Hall A, Wilkinson R, Dadaev T, Goh C, Easton D; UKGPCS Collaborators, Goldgar D, Eeles R.

    Br J Cancer. 2011 Oct 11;105(8):1230-4. doi: 10.1038/bjc.2011.383. Epub 2011 Sep 27.

    PMID:
    21952622
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    15.

    Upregulated FGFR1 expression is associated with the transition of hormone-naive to castrate-resistant prostate cancer.

    Armstrong K, Ahmad I, Kalna G, Tan SS, Edwards J, Robson CN, Leung HY.

    Br J Cancer. 2011 Oct 25;105(9):1362-9. doi: 10.1038/bjc.2011.367. Epub 2011 Sep 27.

    PMID:
    21952621
    [PubMed - indexed for MEDLINE]
    16.

    Suitability of PSA-detected localised prostate cancers for focal therapy: experience from the ProtecT study.

    Catto JW, Robinson MC, Albertsen PC, Goepel JR, Abbod MF, Linkens DA, Davis M, Rosario DJ, Warren AY, Varma M, Griffiths DF, Grigor KM, Mayer NJ, Oxley JD, Deshmukh NS, Lane JA, Metcalfe C, Donovan JL, Neal DE, Hamdy FC; ProtecT study group.

    Br J Cancer. 2011 Sep 27;105(7):931-7. doi: 10.1038/bjc.2011.314. Epub 2011 Aug 23.

    PMID:
    21863028
    [PubMed - indexed for MEDLINE]
    17.

    New tricks with old dogs: personalised medicine and clinical trials.

    Koziol JA.

    Br J Cancer. 2011 Aug 23;105(5):599-601. doi: 10.1038/bjc.2011.299.

    PMID:
    21863035
    [PubMed - indexed for MEDLINE]
    18.

    Body mass index in early and middle-late adulthood and risk of localised, advanced and fatal prostate cancer: a population-based prospective study.

    Discacciati A, Orsini N, Andersson SO, Andrén O, Johansson JE, Wolk A.

    Br J Cancer. 2011 Sep 27;105(7):1061-8. doi: 10.1038/bjc.2011.319. Epub 2011 Aug 16.

    PMID:
    21847119
    [PubMed - indexed for MEDLINE]
    19.

    Ethnic differences in prostate cancer.

    Kheirandish P, Chinegwundoh F.

    Br J Cancer. 2011 Aug 9;105(4):481-5. doi: 10.1038/bjc.2011.273.

    PMID:
    21829203
    [PubMed - indexed for MEDLINE]
    20.

    Genetic architecture of prostate cancer in the Ashkenazi Jewish population.

    Vijai J, Kirchhoff T, Gallagher D, Hamel N, Guha S, Darvasi A, Lencz T, Foulkes WD, Offit K, Klein RJ.

    Br J Cancer. 2011 Sep 6;105(6):864-9. doi: 10.1038/bjc.2011.307. Epub 2011 Aug 9.

    PMID:
    21829199
    [PubMed - indexed for MEDLINE]

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk